ITCI vs. VKTX, JAZZ, CYTK, CERE, ELAN, IONS, ASND, APLS, LEGN, and BPMC
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Cerevel Therapeutics (CERE), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
Viking Therapeutics presently has a consensus price target of $112.25, suggesting a potential upside of 51.06%. Intra-Cellular Therapies has a consensus price target of $90.17, suggesting a potential upside of 23.08%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, equities analysts clearly believe Viking Therapeutics is more favorable than Intra-Cellular Therapies.
In the previous week, Viking Therapeutics had 10 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 30 mentions for Viking Therapeutics and 20 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.81 beat Viking Therapeutics' score of 0.66 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics received 94 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 67.34% of users gave Intra-Cellular Therapies an outperform vote.
Viking Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Viking Therapeutics has higher earnings, but lower revenue than Intra-Cellular Therapies. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -30.08%. Intra-Cellular Therapies' return on equity of -18.41% beat Viking Therapeutics' return on equity.
Summary
Viking Therapeutics beats Intra-Cellular Therapies on 14 of the 17 factors compared between the two stocks.
Get Intra-Cellular Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Intra-Cellular Therapies Competitors List
Related Companies and Tools